## ACHC: Acadia Healthcare Company, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.32 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($12.24)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 5)

**1. Bronstein, Gewirtz & Grossman, LLC Is Investigating Acadia Healthcare Company, Inc. (ACHC) And Encourages Stockholders to Connect**
- Source: WJTV | 20251214T160938 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Acadia Healthcare Company, Inc. (ACHC) for alleged corporate wrongdoing. The firm is encouraging stockholders who purchased Acadia Healthcare securities before February 28, 2020, and still hold them, to connect and assist with the investigation. The investigation focuses on whether the company's officers and/or directors engaged in misconduct.

**2. Acadia Healthcare Company, Inc. (ACHC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation**
- Source: Fox 59 | 20251214T160938 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Acadia Healthcare Company, Inc. (ACHC) following Acadia's disclosure of higher anticipated patient-related litigation costs and a reduced outlook for full-year 2025 Adjusted EBITDA. The investigation focuses on Acadia's stock price drop after this news. Shareholders are encouraged to contact the firm for more information.

**3. Acadia Healthcare Company, Inc. (ACHC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation**
- Source: WFXR News | 20251211T230907 | Somewhat-Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Acadia Healthcare Company, Inc. (ACHC) for corporate wrongdoing. The firm encourages stockholders who purchased ACHC securities before February 28, 2020, and still hold them, to contact them for more information and to assist in the investigation. The representation of investors in class actions is on a contingency fee basis.

**4. Bronstein, Gewirtz & Grossman, LLC Encourages Acadia Healthcare Company, Inc. (ACHC) Stockholders to Inquire about Securities Investigation**
- Source: SiouxlandProud | 20251211T161004 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Healthcare Company, Inc. (ACHC) securities. This investigation follows Acadia's disclosure on December 2, 2025, that it expects higher expenses related to patient-related litigation, leading to a reduction in its full-year 2025 Adjusted EBITDA guidance and a significant increase in projected PLGL expenses. As a result, Acadia's stock price dropped, prompting the firm to encourage affected stockholders to inquire about the securities investigation.

**5. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Acadia Healthcare Company, Inc. (ACHC) and Encourages Investors to Learn More About the Investigation**
- Source: WRIC ABC 8News | 20251210T230907 | Somewhat-Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Acadia Healthcare Company, Inc. (ACHC) on behalf of investors. This follows Acadia's disclosure on December 2, 2025, that it expects higher patient-related litigation costs, leading to a reduction in its full-year 2025 Adjusted EBITDA guidance. Investors are encouraged to learn more about the investigation.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 10)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Barclays | $14 | $17 | -18% |
| 2025-12-03 | RBC Capital | $19 | $22 | -14% |
| 2025-12-03 | Cantor Fitzgera | $17 | $22 | -23% |
| 2025-12-03 | Keybanc | $25 | $30 | -17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Barclays | main | Equal-Weight |
| 2025-12-03 | RBC Capital | main | Outperform |
| 2025-12-03 | Cantor Fitzgera | main | Neutral |
| 2025-12-03 | Keybanc | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 0 |

**Top Holders:**
- Blackrock Inc.: 11.9% (+20.4%)
- Vanguard Group Inc: 10.2% (+7.8%)
- Wellington Managemen: 10.2% (+11.8%)
- FMR, LLC: 6.6% (+2.2%)
- Khrom Capital Manage: 5.5% (+103.0%)

### Key Risks

1. High short interest (18.7%, 5.5 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 37.7% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.32 suggests fair value with growth premium. Analyst sentiment negative (10 target cuts vs 0 raises). Institutional flow bullish (9 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 0.90 |
| 52W Range | $12.63 - $47.08 |
| Short Interest | 18.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.32 |
| Forward P/E | 7.2 |
| Current P/E | 6.8 |
| YoY Growth | -5.3% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from -14.0% to -6.9% (+7.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 10.9pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.7%) - potential reversal signal. AM_20 at -6.6% indicates price below own 20MA trend. Underperforming sector by 6.7pp, stock-specific weakness. Below SMA200 (0.62x), long-term trend not supportive. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.94% (CS: 4) | Weak |
| RSI_14 | 34.6 | Neutral |
| MACD Histogram | 0.09 | Bullish |
| vs SMA20 | 0.934x | Below |
| vs SMA50 | 0.723x | Below |
| vs SMA200 | 0.623x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $14.28
- **Stop Loss:** $12.24 (14.3% risk)
- **Target:** $18.36 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 490
- **Position Value:** $6,997.20
- **Portfolio %:** 7.00%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-26 (Est: $0.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.66 | $0.72 | +9.2% |
| 2025Q2 | $0.71 | $0.83 | +17.4% |
| 2025Q1 | $0.36 | $0.40 | +12.0% |
| 2024Q4 | $0.71 | $0.64 | -10.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*